Clinico-pathological factors of long-surviving (more than 3 years) lung cancer patients who did not undergo resection (n=13) were compared with those of patients with resections. The latter group was comprised of short-survival (less than 3 years) (n=11) cases of pathological stagelA (T1NOMO) carcinomas. The average survival time of the long-surviving group was 51.8 months and that of the short-surviving group was 21.5 months. Chemotherapy was the most frequently used treatment (7/13, 53.8%) in the first group, in which CDDP was combined with radiotherapy. Pathological examinations from the group with resected stage IA primary tumors revealed microscopic blood vessel invasion in 6/11 cases (54.5%) and lymphatic vessel invasion in 2/11 cases (18.2%). The first relapse sites in this group were usually distant metastases. There were more females, and patients older than 75 years in the long-surviving group, and we also observed a greater number of squamous cell carcinomas in the first group (X2-test, p<0.05). We therefore conclude that certain factors might relate to better prognosis, namely, being female and of a more advanced age, as well as the presence of squamous cell carcinoma in particular. Furthermoer, microscopic blood vessel invasion is one of the risk factors for distant metastases resulting in premature death following surgery.
The overall survival rate of lung cancer is still poor in comparison with that of other organ-specific cancers.
Even in case of absolute cure following operations performed in patients with p-stage I lung cancers, about 30%
of these patients will die within 5 years because of intrathoracic recurrences or distant metastases1,2). However, it is also true that there are some patients who survive for a relatively long time with the burden of a tumerous growth. This phenomenon might be explained by two factors:
1. the biological features of the cancer cells (e.g. slow growth rate, low-grade invasiveness, and low potentiality for distant metastases) and 2. immunological antitumor responses of the host. By analysing long-surviving lung cancer patients who did not undergo tumor resection, we may obtain some useful information for predicting the prognosis of non-resectable lung cancers, and perhaps then we can develop methods of effective treatment for these cancers. We chose patients who survived more than 3 years without resection of the primary tumor. The computer data base of lung cancer patients who had been treated in the Department of Surgery of Tokyo Medical College Hospital was screened to locate patients who survived more than 3years without resection (group of patients whose lung cancer could not be resected, but survived for a long time: N-L group) and also p-stage IA patients who died within 3 years after an absolutely curative operation (group of patients whose lung cancer could be resected, but survived for a short time: R-S group). Thirteen cases in the N-L group and 11 cases in the R-S group were selected.
The definitive diagnosis of the N-L group was confirmed by histological and/or cytological examination of the primary lung tumor. All N-L patients had followedup outpatient care in our department for at least 36 months.
The recent status of cellular immunity was observed in 3 of the N-L cases. In the study, we used the following immunological tests: PPD (purified protein derivatives) skin reaction, lymphoblastoid reaction stimulated by PHA (phytohemagglutinin)3), ADCC (antibody-dependent cell-mediated cytotoxicities)4), NK (natural killer cell) activities against K562 leukemia cells5), and the *Department of Surgery , Tokyo Medical College Hospital Correspondence to : Haruhiko Nakamura, Department of Surgery, Tokyo Medical College Hospital, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, Japan Statistical significance between the N-L group and the R-S group was analysed by X2-test.
Results
A summary of the long-surviving lung cancer patients who did not undergo resection is shown in Table 1 (7 males, 6 females). The average age at the time of diagnosis was 68.8 years. Histologically, we observed adenocarcinoma in 6/13, squamous cell carcinoma in 4/13, small cell carcinoma in 2/13, and large cell carcinoma in 1/13. Clinically, 2/13 were in stage I , 1/13 in stage II, 3/13 in stage III A, 4/ 13 in stage III B and 3/13 in stage IV. All stage IV cases had pulmonary metastases. Resection was not performed in stage I and II cases because of patient refusal. The most frequently used treatment in this group was chemo-radiotherapy. Seven cases (53.8%) were treated with CDDP combined with Lineac irradiation. In two cases, bronchial artery injection (BAI) of CDDP was employed combined with radiotherapy. Chemotherapy alone was performed in 5cases (38.5%). In 4 of those 5 cases, CDDP was used. One 86 year-old female was only treated with the immunopotentiator OK432 (Chugai, Tokyo) made from components of streptococci. In the N-L group, the shortest survival period was 37 months and the longest was 81 months. The average survival time was 51.8 months.
Examination results of the skin reaction for PPD, lymphoblastoid reaction stimulated by PHA, ADCC, NK activity, and subset analyses of the peripheral blood lymphocytes in cases 10, 12, and 13 are shown in Tabble 2. In case 10, lymphoblastoid reaction was suppressed and the proportions of CD3-positive and CD4-positive cells were relatively low. In case 12, NK activity was slightly suppressed and the proportion of CD3-positive cells was slightly diminished. In case 13, lymphoblastoid reaction and NK activity were both suppressed. Though the ADCC in all 3 cases were well-preserved, several other factors in cellular immunity were suppressed, and no evidence of activation of anti-tumor immunity was found.
A summary of the case histories of the stage IA lung cancer who died within 3 years of tumor resection is shown in Table 3 . The presented cases were comprised of 9males and 2 females. Average age at diagnosis was 64.1 years. Histologically, we observed adenocarcinoma in 8/ 11 and large cell carcinoma in 3/11. The differentiation grades of adenocarcinoma were poorly differentiated in 3/11, moderately differentiated in 3/11, and well-differentiated in 2/11. The average of the longest dimension of the primary tumors was 2.3cm. Lobectomy with standard mediastinal lymph node dissection (R2a) was performed in all cases, and all dissected lymph nodes were negative for metastases. The shortest survival period was 13 months and the longest was 35 months. The average survival time was 21.5 months. The first recurrent sites were known in 8/11 cases; 2/ 11 cases occured in the brain, 2/11 cases in the lungs, 2/11 cases in the bone, I case in the pleural cavity and 1 case in the meningeal membrane of the spinal cord. Thus, most recurrences occurred as distant hematogenic metastases. Pathological examinations of the resected primary tumors revealed microscopic blood vessel invasion in 6/11 cases (54.5%) and lymphatic vessel invasion in 2/11 cases (18.2%). The proportion of females in the N-L group (54.5%) was greater than that in the R-S group (18.2%) (X2-test, p<0.05). The proportion of squamous cell carcinoma in the N-L group (36.4%) was greater than that in the R-S group (0%) (X2-test, p<0.05). The proportion of patients older than 75 years in the N-L group (27.3%) was greater than that in the R-S group (0%) (X2-test, p<0.05).
Discussion
This report demonstrates that lung cancer patients have a better prognosis when the tumor is locally wellcontrolled and occurs without distant metastasis. Even inoperable stage III B or IV lung cancer patients can live relatively long, if additional distant metastases do not appear. On the other hand, patients with resected stage I lung cancers have only a short-term survival expectation, if distant metastases appear soon after the operation. Comparing these 2 groups, we found that being female, and of an older age (75 years or more) might prove to be positive prognostic factors, as well as the presence of a squamous cell carcinoma type of tumor as opposed to other types of malignancy.
Takifuji et al.7) analysed factors affecting survival in 199 patients with advanced NSCLC (non-small cell lung cancers) and stated that female gender, chemotherapy (CDDP, vindesine, and mitomycin C), squamous cell carcinoma, and no weight loss were significantly predictive of response outcome. Albain et al.8) analysed 2531 extensive-stage NSCLC and found that good performance status, female gender, and age greater than or equal to 70 years were significant independent predictors of good prognosis. Albain and colleagues also mentioned that the use of CDDP was an additional independent predictor of improved prognosis. These results are all similar to our findings. In addition, Shimizu et al.9) reported that the 5-year survival rate of females with stage I lung cancer is significantly better than that of males. Thus, the prognosis of female lung cancer cases may be better than male cases, both in the early and advanced stages.
Different authors have also reported that the prognosis of female SCLC (small cell lung cancer) patients was also better than that of males. Wolf et al.10) noted that female patients with SCLC had a higher complete remission rate, a superior median survival, and a more favorable 2-year survival rate. Stahel10) and Diggs12) also pointed out the superior survival rate of females with SCLC. Thus, good prognosis might be obtained in female SCLC cases as well as in female NSCLC cases. The reason for the survival advantage in female patients with lung cancer is unknown. The hormonal environment may play an important role, but further investigations are necessary .
Among long-surviving, non-resected NSCLC cases , 36.4% were squamous cell carcinomas. None of the R-S group, p-stage IA NSCLC had squamous cell carcinomas. This is not surprising, because the prognosis of squamous cell carcinoma is considered to be better than that of adenocarcinoma, due to the lower probability of distant metastasis.
Immunological response is thought to be an important factor for the long-term survival of cancer patients3,13).We examined cellular immunity in 3 of the N-L cases. However, no evidence of activation of cellular immunity was found. Moreover, HK activity was suppressed in 2/3 cases. Since those 2 patients are living with recurrent tumors, immunological response might be suppressed even in long-surviving cases, if the tumor exists in the body.
In many other reports, chemotherapy with CDDP was a statistically significant factor associated with good prognosis7,8). CDDP was used in 11/13 (84.6%) in our N-L cases. Especially when CDDP was combined with radiotherapy, it seemed to be the most effective method for the local control of lung cancer. As a rule, in our institution, post-operative chemotherapy using CDDP is not performed in stage I cases.
In short-surviving stage I cases, three were poorly differentiated adenocarcinomas and three were large cell carcinomas. This means 6/11 (54.5%) of the cases with unusually poor prognoses were poorly differentiated. Sobue et al.14) reported that poorly differentiated adenocarcinoma showed a 2.01 times higher risk of death than well-or moderately differentiated adenocarcinoma.
Smoking is also considered to be one of the worst prognostic factors. In the N-L group, 5females (38.5%) were non-smokers, whereas only 2 females (18.2%) in the R-S group were non-smokers. However, because of the small number of patients in this study, it is difficult to discuss the influence of smoking on prognosis.
In conclusion, the ratio of N-L patients with squamous cell carcinoma, who were in female gender, and whose age was more the 75 years was respectively greater than in the R-S group. Poorly differentiated adenocarcinomas or large cell carcinomas and the presence of microscopic blood vessel invasion indicated poor prognosis. If a resected lung carcinoma shows these features, the patient's follow-up care should include regular and through examination for possible distant metastasis.
